Trial Profile
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BioNTech
- 09 Nov 2023 Planned End Date changed from 2 Jun 2025 to 11 Aug 2025.
- 09 Nov 2023 Planned primary completion date changed from 2 Jun 2025 to 11 Aug 2025.
- 18 Oct 2023 Planned number of patients changed from 3020 to 3692.